• Inhibrx Biosciences reported interim Phase 2 results from HexAgon, a first-line head and neck cancer study testing INBRX-106 with pembrolizumab versus pembrolizumab alone.
• Early readout showed the combination produced more confirmed tumor responses than PD-1 monotherapy, with deeper reductions in responding patients and complete responses seen only in the combination arm.
• Immune monitoring pointed to stronger systemic T-cell expansion with the combination, supporting a potential costimulatory effect beyond checkpoint inhibition alone.
• Safety was described as manageable for an immunotherapy combination, with no treatment-related deaths reported.
• Progression-free survival data are expected in Q4 2026; Phase 3 start is planned for Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605110800PR_NEWS_USPR_____LA55751) on May 11, 2026, and is solely responsible for the information contained therein.